News & Blog
News & Blog
Lexeo Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
FARA Celebrates the 15th Annual Ataxian Athlete Initiative (AAI) for People with Ataxia
May 2023 – Advocacy Newsletters
Meet the Community – Vezirka Bećić
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort – First Quarter 2023 Financial Results
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohor
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
Meet the Community – Alijana Shakya
April 2023 – Advocacy Newsletter
